Dr. Chou's research laboratory focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and how these become disrupted in hematologic diseases.
Dr. Chou focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and the pathophysiology of pediatric hematologic diseases.
Looking at a scientific problem from new and different perspectives is what research is all about, which is why Children's Hospital of Philadelphia's Research Institute is dedicated to cultivating a more diverse workforce. "We value diversity within our research community and it is undoubtedly part of what makes us successful," wrote Bryan A. Wolf, MD, PhD, Chief Scientific Officer and Director
First produced in the past decade, induced pluripotent stem cells — which are derived from adult cells — are capable of developing into many cell types. In two new studies, investigators from The Children’s Hospital of Philadelphia reprogrammed skin cells from patients with rare disorders into induced pluripotent stem cells (iPSCs), highlighting the great promise these cells hold.
